Pharmacokinetics of thalidomide in an elderly prostate cancer population

Journal of Pharmaceutical Sciences

Volumn 88, Issue 1, 1999, Pages 121-125

  Figg, William D ^a   Raje, Sangeeta ^a   Bauer, Kenneth S ^a   Tompkins, Anne ^a   Venzon, David ^a   Bergan, Raymond ^a   Chen, Alice ^a   Hamilton, Michael ^a   Pluda, James ^a   Reed, Eddie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEADY STATE;

EID: 0032903830     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980172i     Document Type: Article

References (28)

1. Kluken, N.; Wente, W. Indications for thalidomide therapy for leprosy. Int. J. Dermatol. 1974, 13, 20-25.
2. Sharpstone, D.; Rowbottom, A.; Nelson, M.; Gazzard, B. The treatment of microsporideal diarrhea with thalidomide. AIDS 1995, 9, 658-659.
3. Vincente, T.; Ortega, A.; Munoz, P.; Diaz, M.D.; Bouza, E. In vitro activity of thalidomdie against Mycobacterium avium complex. Arch. Intern. Med. 1993, 153, 534.
4. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 1994, 97, 4082-4085.
5. Bauer, K. S.; Dixon, S. C.; Figg, W. D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharm. 1998, 55, 1827-1834.
6. Simmons, B. R.; Lush, R. M.; Figg, W. D. A reversed-phase high performance liquid chromatography method using solidphase extraction to quantitate thalidomide in human serum. Anal. Chim. Acta 1997, 339, 91-97.
7. Huupponen, R.; Pyykko, K. Stability of thalidomide in plasma. Clin. Chem. 1995, 41, 1199.
8. Eriksson, T.; Bjorkman, S.; Roth, B.; Fyge, A.; Hoglund, P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humnas of the enantiomers of thalidomide. Chirality 1995, 7 (1), 44-52.
9. Eriksson, T.; Bjorkman, S.; Roth, B.; Fyge, A.; Hoglund, P. Enatiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. Chirality 1998, 10, 223-228.
10. Heney, D.; Norfolk, D. R.; Wheeldon, J.; Bailey, C. C.; Lewis, I. J.; Barnard, D. L. Thalidomide treatment for chronic graft-versus-host disease. Br. J. Haematol. 1991, 78, 23-27.
11. Czejka, M. J.; Koch, H. P. Determination of thalidomide and its major metabolites by high-performance liquid chromatography. J. Chromatogr. 1987, 413, 181-187.
12. D'Argenio, D. Z.; Schumitsky, A. ADAPT II User's Guide, Biomedical Simulations Resource; University of Southern California: Los Angeles, CA.
13. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
14. Folkman, J. Angigenesis in cancer, vascular, rheumatoid and other diseases. Natl. Med. 1995, 1, 27-31.
15. Fabro, S.; Schumacher, H.; Smith, R. L.; Stagg, R. B. L.; Williams, R. T. The metabolism of thalidomide: some biological effects of thalidomide and it's metabolites. Br. J. Pharmacol. 1985, 25, 352-362.
16. Gibaldi, M.; Perrier, D. Pharmacokinetics, 2nd ed.; Marcel Dekker: New York.
17. Gordon, G. B.; Spielberg, S. P.; Blake, D. A.; Balasubramanian, V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci.; U.S.A. 1981, 78, 2545-2548.
18. Jusko, W. J. Guidelines for collection and analysis of pharmacokinetic data. In Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed.; Evans, W. E.; Schentag, J. J.; Jusko, W. J., Eds.; Applied Therapeutics: Vancouver, WA.
19. Kenyon, B. M.; Browne, F.; D'Amato, R. J. Effects of thalidomdie and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 1997, 64, 971-978.
20. Moreira, A. L.; Sampaio, E. P.; Zmuidzinas, A.; Frindt, P.; Smith, K. A.; Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation. J. Exp. Med. 1993, 177, 1675-1680.
21. Pollard, M. Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. Cancer Lett. 1996, 101, 21-24.
22. Piscitelli, S. C.; Figg, W. D.; Hahn, B.; Kelly, G.; Thomas, S.; Walker, R. E. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 1997, 41 (12), 2797-2799.
23. Schmahl, H. J.; Nau, H.; Neubert, D. The enantiomers of the teratogenic thalidomdie analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey. Arch. Toxicol. 1988, 62, 200-204.
24. Schumacher, H.; Blake, D. A.; Gillette, J. R. Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 1968, 160, 201-211.
25. Weidner, N.; Semple, J. P.; Welch, W. R.; Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 1991, 324, 1-8.
26. Weidner, N.; Carroll, P. R.; Flax, J.; Blumenfeld, W.; Folkman, J.; Tumor angigenesis correlates with metastatsis in invasive prostate carcinoma. Am. J. Pathol. 1993, 143, 401-409.
27. Yamaoka, K.; Nakagawa, T.; Uno, T. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 1978, 6, 165-175.
28. Chen, T. L.; Vogelsang, G. B.; Petty, B. G.; Brundrett, R. B.; Noe, D. A.; Santos, G. W.; Colvin, O. M. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab. Dispos. 1989, 17, 402-405.